Oral AntiCOVID-19 Medicationsa Game Changer? - Frankly Speaking Ep 263

Published: Feb. 14, 2022, 5:30 a.m.

b'Credits: 0.25 AMA PRA Category 1 Credit\\u2122 \\xa0 CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-263 \\xa0 Overview: The FDA\\u2019s recent emergency use authorization (EUA) for oral agents to treat COVID-19 means that primary care providers (PCPs) will be on the frontline of treating patients with COVID-19. Therefore, PCPs must understand who is eligible for such treatments and how to prescribe them. We will discuss the results of the recent FDA EUA for Pfizer\\u2019s Paxlovid and Merck\\u2019s molnupiravir antiviral agents and give you the information you need to confidently prescribe them. \\xa0 Episode resource links: FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR MOLNUPIRAVIR (fda.gov) FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVID (fda.gov) Guest: Robert A. Baldor MD, FAAFP \\xa0 Music Credit: Richard Onorato'